149 related articles for article (PubMed ID: 33788733)
1. The Clinical Utility of Serum CXCR-2 Assessment in Colorectal Cancer (CRC) Patients.
Pączek S; Łukaszewicz-Zając M; Gryko M; Kulczyńska-Przybik A; Mroczko B
Anticancer Res; 2021 Mar; 41(3):1421-1428. PubMed ID: 33788733
[TBL] [Abstract][Full Text] [Related]
2. CXCL-8 in Preoperative Colorectal Cancer Patients: Significance for Diagnosis and Cancer Progression.
Pączek S; Łukaszewicz-Zając M; Gryko M; Mroczko P; Kulczyńska-Przybik A; Mroczko B
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32192002
[No Abstract] [Full Text] [Related]
3. Comparison between Clinical Utility of CXCL-8 and Clinical Practice Tumor Markers for Colorectal Cancer Diagnosis.
Huang Z; Li Z; Chen X; Zhu X; Zhang J; Song Y; Cao Y; Lu P
Biomed Res Int; 2022; 2022():1213968. PubMed ID: 36567905
[TBL] [Abstract][Full Text] [Related]
4. Specific Receptors for the Chemokines CXCR2 and CXCR4 in Pancreatic Cancer.
Litman-Zawadzka A; Łukaszewicz-Zając M; Gryko M; Kulczyńska-Przybik A; Kędra B; Mroczko B
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867211
[TBL] [Abstract][Full Text] [Related]
5. Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer.
Song YF; Xu ZB; Zhu XJ; Tao X; Liu JL; Gao FL; Wu CL; Song B; Lin Q
Clin Transl Oncol; 2017 Apr; 19(4):519-524. PubMed ID: 27743169
[TBL] [Abstract][Full Text] [Related]
6. Serum concentrations of receptor for interleukin 8 in patients with esophageal cancer.
Łukaszewicz-Zając M; Kulczyńska-Przybik A; Muszyński P; Kozłowski M; Szmitkowski M; Mroczko B
Pol Arch Med Wewn; 2016 Oct; 126(11):854-861. PubMed ID: 27906878
[TBL] [Abstract][Full Text] [Related]
7. Serum chemokine CXCL8 as a better biomarker for diagnosis and prediction of pancreatic cancer than its specific receptor CXCR2, C-reactive protein, and classic tumor markers CA 19-9 and CEA.
Litman-Zawadzka A; Łukaszewicz-Zając M; Gryko M; Kulczyńska-Przybik A; Mroczko B
Pol Arch Intern Med; 2018 Sep; 128(9):524-531. PubMed ID: 30057378
[TBL] [Abstract][Full Text] [Related]
8. Serum Expression of
Li S; Huang M; Liu Q; Wang D; Wu R; Zhang X; Chen W; Duan L
Dis Markers; 2019; 2019():5070524. PubMed ID: 31781302
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic significance of serum HMGB1 in colorectal carcinomas.
Lee H; Song M; Shin N; Shin CH; Min BS; Kim HS; Yoo JS; Kim H
PLoS One; 2012; 7(4):e34318. PubMed ID: 22496788
[TBL] [Abstract][Full Text] [Related]
10. Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer.
Lukaszewicz-Zając M; Mroczko B; Gryko M; Kędra B; Szmitkowski M
Clin Exp Med; 2011 Jun; 11(2):89-96. PubMed ID: 20938721
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of carcinoembryonic antigen and carcinoma antigen 19-9 for colorectal carcinoma.
Zhang SY; Lin M; Zhang HB
Int J Clin Exp Pathol; 2015; 8(8):9404-9. PubMed ID: 26464695
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule EpCAM (GA733-2), and carbohydrate antigen 19-9 (CA 19-9) levels in colorectal cancer patients and correlation with clinicopathological characteristics.
Mourtzikou A; Stamouli M; Kroupis C; Christodoulou S; Skondra M; Kastania A; Pectasides D; Athanasas G; Dimas C
Clin Lab; 2012; 58(5-6):441-8. PubMed ID: 22783573
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic value of serum IL-23 in colorectal cancer.
Elessawi DF; Alkady MM; Ibrahim IM
Arab J Gastroenterol; 2019 Jun; 20(2):65-68. PubMed ID: 31155425
[TBL] [Abstract][Full Text] [Related]
14. The evaluation of diagnostic value of the tumor markers: CCSA-2 and CEA in colorectal cancer.
Knychalski B; Lukieńczuk T
Pol Przegl Chir; 2012 Feb; 84(2):86-92. PubMed ID: 22487741
[TBL] [Abstract][Full Text] [Related]
15. Identification of mannose receptor and CD163 as novel biomarkers for colorectal cancer.
Ding D; Yao Y; Yang C; Zhang S
Cancer Biomark; 2018 Feb; 21(3):689-700. PubMed ID: 29226859
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of serum IGFBP-3 in colorectal cancer.
Hou YL; Luo P; Ji GY; Chen H
J Clin Lab Anal; 2019 Jul; 33(6):e22912. PubMed ID: 31218761
[TBL] [Abstract][Full Text] [Related]
17. Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Colorectal Cancer.
Kunizaki M; Sawai T; Takeshita H; Tominaga T; Hidaka S; To K; Miyazaki T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2016 Aug; 36(8):4171-5. PubMed ID: 27466527
[TBL] [Abstract][Full Text] [Related]
18. Serum CCL20 combined with IL-17A as early diagnostic and prognostic biomarkers for human colorectal cancer.
Wang D; Yuan W; Wang Y; Wu Q; Yang L; Li F; Chen X; Zhang Z; Yu W; Maimela NR; Cao L; Wang D; Wang J; Sun Z; Liu J; Zhang Y
J Transl Med; 2019 Aug; 17(1):253. PubMed ID: 31387598
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 protein in the serum of patients with colorectal cancer: Correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor.
Abdel-Aziz MM; Lotfy M; El-Kady IM; Abozaid M
Cancer Detect Prev; 2009; 32(4):329-35. PubMed ID: 16632243
[TBL] [Abstract][Full Text] [Related]
20. Exploration of the application potential of serum multi-biomarker model in colorectal cancer screening.
Xu R; Shen J; Song Y; Lu J; Liu Y; Cao Y; Wang Z; Zhang J
Sci Rep; 2024 May; 14(1):10127. PubMed ID: 38698075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
